Advanced search

Authors whose works are in public domain in at least one jurisdiction

List of works by Faith E Davies

51-100 of 109 results

View this query on the Wikidata Query Service
The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma

scientific article
Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis

scientific article published on 01 October 2018
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial.

scientific article published on 9 December 2016
Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma.

scientific article
Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients

scientific article published on 07 February 2019
Identification of Autophosphorylation Inhibitors of the Inositol-Requiring Enzyme 1 Alpha (IRE1α) by High-Throughput Screening Using a DELFIA Assay

scientific article published on November 8, 2012
Neutral tumor evolution in myeloma is associated with poor prognosis.

scientific article published on 21 August 2017
A stressful life (or death): Combinatorial proteotoxic approaches to cancer-selective therapeutic vulnerability

scientific article published on April 1, 2011
Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma.

scientific article published on 20 December 2018
Sub-clonal copy number is associated with prognosis in multiple myeloma

scientific article published on 29 October 2018
A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study

scientific article published on 06 February 2019
A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma.

scientific article published on 5 September 2017
Update on the optimal use of bortezomib in the treatment of multiple myeloma

scientific article
The role of next generation sequencing in infection prevention in human parainfluenza virus 3 infections in immunocompromised patients.

scientific article published on 12 May 2017
Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial

scientific article published on April 20, 2015
Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients

scientific article
Toward personalized treatment in multiple myeloma based on molecular characteristics

scientific article published on 26 December 2018
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation

scientific article published on February 2, 2015
Response evaluation and monitoring of multiple myeloma

scientific article published on February 2014
CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy

scientific article published on 17 October 2006
Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials

scientific article published on 20 June 2018
The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma

scientific article published on 21 March 2018
Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study

scientific article published on 09 July 2018
Kinase domain activation through gene rearrangement in multiple myeloma.

scientific article published on 23 March 2018
The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial

scientific article published on 14 October 2019
Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of

scientific article published on 22 January 2019
The use of biological variables to predict outcome in multiple myeloma

scientific article published on December 1, 1997
The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFκB signalling pathway

scientific article published on July 2015
The safety of pomalidomide for the treatment of multiple myeloma

scientific article published on 25 February 2016
Inhibiting the molecular evolution of cancer through HSP90

scientific article published on October 1, 2012
The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma

scientific article published on March 10, 2015
A novel functional role for MMSET in RNA processing based on the link between the REIIBP isoform and its interaction with the SMN complex

scientific article
Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

scientific article published on 14 October 2019
Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma

scientific article published on 13 July 2018
Cardiovascular complications of multiple myeloma in the elderly.

scientific article published on 22 November 2017
Practical Considerations for Antibodies in Myeloma

scientific article published on 01 May 2018
Is molecular remission the goal of multiple myeloma therapy?

scientific article published in December 2017
A gene expression based predictor for high risk myeloma treated with intensive therapy and autologous stem cell rescue.

scientific article published on 19 August 2014
The genomic landscape of plasma cells in systemic light chain amyloidosis

scientific article published on 16 November 2018
Oncogenic RAC1 and NRAS drive resistance to endoplasmic reticulum stress through MEK/ERK signalling.

scientific article published on 9 January 2018
Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach.

scientific article published on 16 June 2017
Long-term outcomes after autologous stem cell transplantation for multiple myeloma

scientific article published on 01 January 2020
Monoclonal Antibody Therapy in Multiple Myeloma: Where do we Stand and Where Are We Going?

scientific article published on February 17, 2016
MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma

scientific article published on 6 July 2018
Bacteremias following autologous stem cell transplantation for multiple myeloma: Risk factors and outcomes

scientific article published on 15 February 2019
BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma

scientific article published on 27 January 2020
Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120).

scientific article published on 25 March 2016
The bone marrow microenvironment influences the differential chemokine receptor expression of normal and neoplastic plasma cells

scientific article published on 01 June 2005
Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma

scientific article published in May 2024
Supplementary Table from Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

Paulina is supported by:

About Paulina

Help